Distributing Is Not Licensing: PDL BioPharma Loses Patent, Royalty Battle With MedImmune
This article was originally published in The Pink Sheet Daily
Executive Summary
A California federal court rules that a PDL patent claim is invalid and that MedImmune did not have to pay royalties on sales by its ex-U.S. distributor Abbott; MedImmune may seek repayment of $280 million in royalties.
You may also be interested in...
Generic Competition And Pricing Pressures Hold Back AstraZeneca In The First Quarter
AstraZeneca reports declines in revenues and operating profits in the 2011 first quarter, but expects its earnings per share will be boosted this year from tax and patent settlements.
Generic Competition And Pricing Pressures Hold Back AstraZeneca In The First Quarter
AstraZeneca reports declines in revenues and operating profits in the 2011 first quarter, but expects its earnings per share will be boosted this year from tax and patent settlements.
Facet Says Yes To Abbott's $720 Million Buyout Offer
The antibody specialist said no to Biogen Idec in December and found a better offer of nearly $10 more a share.